Efficacy And Safety of Ologen Augmented Trabeculotomy-Trabeculectomy in Primary Congenital Glaucoma

Abstract

Purpose: To evaluate the efficacy and safety of using Ologen implant as an augmentation to combined trabeculotomy and trabeculectomy surgery (CTT) in patients with primary congenital glaucoma (PCG)

Patients and method: Retrospective analysis of medical records of patients with PCG who had CTT augmented with Ologen implant as a primary surgery were reviewed. 24 patients fulfilled the inclusion criteria and were included in statistical analysis. Patient demographic data, pre-operative examination records as well as the records of follow up visits were recruited to assess for surgical efficacy and recording intra-operative and post-operative complications. Complete success was considered when IOP≤ 16 mmHg without the addition of medical treatment or further glaucoma surgery to lower IOP. Failure was considered when IOP is ˃ 16 mmHg with 3 antiglaucoma topical eye drops or the requirement of another surgical intervention to lower IOP.

Results: 24 patients were included, 22 patients had surgery in one eye, and 2 patients had surgery bilaterally. successful IOP reduction was achieved in 21 eyes (80.7%) and this reduction was maintained during follow up visits. Failure was recorded in 5 eyes (19.2%). Of the reported complications intraoperative hyphema was recorded in 9 eyes (34.6%), improvement of corneal edema was achieved in most cases, as well as reversal of disc cupping. No implant related complications occurred including allergic reaction or graft extrusion.

Conclusion: Ologen implant used as an augmentation for CTT surgery in patients with PCG is a safe and effective adjunctive with high success rate.